← Cronos Group Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($1.2m) |
$2.5m
+309.33%
|
($19.2m)
-870.98%
|
$1.2b
+6173.97%
|
($73.1m)
-106.27%
|
($396.1m)
-441.60%
|
($168.7m)
+57.40%
|
($74.0m)
+56.17%
|
$41.1m
+155.54%
|
($9.4m)
-123.00%
|
— | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($1.2m) | $2.5m | ($19.2m) | $1.2b | ($75.3m) | ($397.2m) | ($168.7m) | ($74.6m) | $40.0m | ($2.9m) | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | — | — | ($932k) | ($2.1m) | ($1.1m) | $0 | ($590k) | ($1.1m) | $6.5m | — | |
| Depreciation, Depletion and Amortization | $382k | $996k | $2.5m | $3.9m | $7.0m | $15.4m | $13.1m | $8.1m | $9.3m | $14.2m | $14.3m | |
| Amortization of Intangible Assets | — | — | — | $646k | $814k | $1.8m | $2.8m | $3.5m | — | — | — | |
| Depreciation, Nonproduction | — | — | — | $1.5m | $2.1m | — | — | — | — | — | $14.3m | |
| Deferred Income Tax Expense (Benefit) | ($568k) | $298k | $489k | $0 | $0 | $40k | ($241k) | $145k | ($266k) | $1.1m | — | |
| Share-based Payment Arrangement, Noncash Expense | — | — | — | $11.6m | $15.4m | $10.2m | $15.1m | $8.8m | $8.7m | $7.0m | $6.5m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | $915k | $2.1m | $13.5m | $2.8m | $1.0m | $1.2m | $3.8m | — | |
| Adjustments For Share-Based Payments | $307k | $1.9m | $4.2m | — | — | — | — | — | — | — | — | |
| Share-based Payment Arrangement, Expense | — | — | — | $11.6m | $15.4m | $10.2m | $15.1m | $8.8m | $8.7m | $7.0m | $6.5m | |
| Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount | — | — | — | — | — | — | $61.4m | $23.4m | $25.6m | $0 | — | |
| Goodwill and Intangible Asset Impairment | — | — | — | — | $40.0m | $236.1m | $0 | $0 | — | $700k | — | |
| Goodwill, Impairment Loss | — | — | — | — | $35.0m | — | — | — | — | — | $14.4m | |
| Operating Lease, Impairment Loss | — | — | — | — | — | $702k | $2.0m | — | — | — | — | |
| Equity Method Investment, Realized Gain (Loss) on Disposal | — | — | — | $15.5m | $4.8m | $0 | $0 | — | — | — | — | |
| Income (Loss) from Equity Method Investments | ($163k) | ($165k) | $936k | ($2.0m) | ($4.5m) | ($6.3m) | $3.1m | $1.6m | $2.4m | $0 | — | |
| Nonoperating Income (Expense) | — | — | — | $1.3b | $106.1m | $163.5m | ($9.7m) | $11.1m | $113.1m | $275k | — | |
| Other Nonoperating Income (Expense) | — | — | — | — | ($1.8m) | $730k | ($493k) | $1.1m | ($350k) | ($241k) | — | |
| Proceeds From Sales Of Investments Other Than Investments Accounted For Using Equity Method | $163k | $10.9m | $967k | — | — | — | — | — | — | — | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | — | — | — | $702k | $4.7m | $13.2m | $2.7m | ($9.2m) | $917k | $16.7m | ($19.6m) | |
| Increase (Decrease) in Inventories | — | — | — | $51.9m | $28.1m | ($11.6m) | $7.2m | ($7.4m) | ($7.4m) | $10.4m | ($9.4m) | |
| Inventory Write-down | — | — | — | $29.4m | $26.1m | $12.0m | $0 | $805k | $707k | $654k | — | |
| Realized fair value adjustments on inventory sold in the year | — | $2.4m | $8.3m | — | — | — | — | — | — | — | — | |
| Increase (Decrease) in Accounts Payable | — | — | — | — | — | ($2.4m) | ($863k) | ($773k) | ($7.4m) | $1.1m | $5.3m | |
| Net Cash Provided by (Used in) Operating Activities | ($6.5m) |
($5.5m)
+14.33%
|
($9.7m)
-75.54%
|
($130.0m)
-1234.91%
|
($142.5m)
-9.58%
|
($153.6m)
-7.83%
|
($88.9m)
+42.10%
|
($42.8m)
+51.84%
|
$18.8m
+143.99%
|
$25.9m
+37.27%
|
$60.1m
+132.17%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | ($1.5m) | ($42.7m) | ($114.4m) | $38.7m | $31.4m | $11.1m | $3.5m | $2.5m | $12.4m | $25.7m | ($10.6m) | |
| Cash, Cash Equivalents, and Short-term Investments | — | — | — | — | — | — | — | — | $858.8m | $831.8m | — | |
| Gain (Loss) on Investments | — | — | — | — | — | — | $17.9m | ($10.5m) | ($3.8m) | ($446k) | $2.8m | |
| Unrealized Gain (Loss) on Investments | — | — | — | — | — | — | $14.7m | ($12.1m) | ($6.2m) | ($446k) | — | |
| Share of loss (income) from investments in equity accounted investees | ($163k) | ($165k) | $936k | — | — | — | — | — | — | — | — | |
| Gain on other investments | — | ($4.9m) | ($221k) | — | — | — | — | — | — | — | — | |
| Investments in equity accounted investees | — | ($1.1m) | ($621k) | — | — | — | — | — | — | — | — | |
| Proceeds from sale of other investments | — | $10.9m | $967k | — | — | — | — | — | — | — | — | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | $224.3m | $0 | $0 | — | — | — | — | — | |
| Payments for (Proceeds from) Other Investing Activities | — | — | — | — | $0 | $0 | ($68k) | ($860k) | $0 | $0 | — | |
| Net Cash Provided by (Used in) Investing Activities | ($8.0m) | ($38.8m) | ($121.5m) | ($603.5m) | $20.1m | ($28.9m) | ($1.8m) | ($59.5m) | $175.1m | ($76.6m) | ($340.5m) | |
| Cash flows from financing activities: | ||||||||||||
| Repayments Of Borrowings Classified As Financing Activities | $2.7m | — | — | — | — | — | — | — | — | — | — | |
| Payments for Repurchase of Common Stock | — | — | — | — | — | — | — | — | — | $9.7m | — | |
| Dividends Received From Associates Classified As Investing Activities | $2k | — | — | — | — | — | — | — | — | — | — | |
| Proceeds from (Payments for) Other Financing Activities | — | — | — | — | — | — | ($68k) | $0 | $0 | — | — | |
| Net Cash Provided by (Used in) Financing Activities | $16.8m |
$50.1m
+197.63%
|
$154.6m
+208.88%
|
$1.9b
+1100.82%
|
($5.5m)
-100.29%
|
($13.4m)
-145.97%
|
($2.9m)
+78.45%
|
($1.0m)
+64.45%
|
($1.2m)
-19.51%
|
($19.9m)
-1516.98%
|
($48.4m)
-143.34%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | — | — | — | $1.2b | ($121.7m) | ($191.1m) | ($122.3m) | ($95.4m) | $189.5m | ($67.0m) | $465.5m | |
| Cash - beginning of year | $3.5m | $9.2m | $32.6m | — | — | — | — | — | — | — | — | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | $1.2b | $1.1b | $887.0m | $764.6m | $669.3m | $858.8m | $791.8m | $465.5m | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | — | — | — | $52.4m | $6.1m | $4.9m | ($28.6m) | $8.0m | ($3.2m) | $3.6m | $1.5m | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $294k | $200k | $870k | — | — | $0 | — | $0 | $0 | $0 | — | |
| Income Taxes Paid, Net | — | — | — | — | — | — | — | $33.0m | $647k | ($6.3m) | — | |
| Additional Financial Items | ||||||||||||
| Adjustments For Decrease Increase In Trade Account Receivable | ($57k) | ($1.0m) | ($3.0m) | — | — | — | — | — | — | — | — | |
| Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net | — | — | — | — | — | — | — | — | $32.5m | $0 | — | |
| Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount | — | — | — | — | — | $8.6m | $14.7m | ($12.0m) | ($6.2m) | ($452k) | — | |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax | — | — | — | — | ($650k) | ($500k) | $0 | — | — | — | — | |
| Equity Securities, FV-NI, Realized Gain (Loss) | — | — | — | $747k | — | — | — | — | — | — | — | |
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | $0 | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | ($115k) | — | — | — | — | — | — | — | |
| Foreign Currency Transaction Gain (Loss), Realized | — | — | — | — | — | — | ($746k) | ($296k) | ($582k) | $191k | — | |
| Foreign Currency Transaction Gain (Loss), Unrealized | — | — | — | — | — | — | ($2.3m) | ($7.3m) | $57.9m | ($28.6m) | — | |
| Gain (Loss) on Derivative Instruments, Net, Pretax | — | — | — | $1.3b | $129.3m | $151.4m | $14.1m | ($85k) | $49k | — | — | |
| General and Administrative Expense | $3.4m | $6.9m | $17.4m | $49.4m | $80.5m | $96.5m | $71.2m | $49.5m | $46.5m | $42.0m | — | |
| Goodwill | $1.8m | $1.8m | $1.8m | $214.8m | $179.5m | $1.1m | $1.0m | $1.1m | $63.5m | $66.5m | $14.4m | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | ($74.6m) | ($396.7m) | ($168.7m) | ($70.4m) | $40.0m | ($2.9m) | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | ($650k) | ($500k) | $0 | ($4.1m) | $0 | $0 | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | ($650k) | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | ($568k) | $298k | $489k | $0 | $1.3m | ($431k) | $34.2m | ($3.2m) | ($3.4m) | ($14.2m) | — | |
| Interest Paid Classified As Financing Activities | $294k | $200k | $185k | — | — | — | — | — | — | — | — | |
| Investment Income, Interest | — | — | — | $29.2m | $18.6m | $9.1m | $22.6m | — | — | — | — | |
| Operating Expenses | — | — | — | $103.6m | $153.5m | $543.1m | $136.8m | $96.7m | $101.7m | $80.2m | — | |
| Proceeds From Issuing Shares | $18.0m | $49.6m | $146.0m | — | — | — | — | — | — | — | — | |
| Financing Receivable, Credit Loss, Expense (Reversal) | — | — | — | — | $2.5m | $12.2m | ($662k) | ($1.5m) | ($10.8m) | $4.9m | — | |
| Purchase Of Intangible Assets Classified As Investing Activities | — | — | $360k | — | — | — | — | — | — | — | — | |
| Restructuring Costs | — | — | — | $4.4m | $0 | $0 | $5.3m | $1.5m | — | — | — | |
| Revenue from Contract with Customer, Including Assessed Tax | — | — | — | $25.6m | $54.4m | $89.5m | $114.5m | $120.3m | $161.8m | $193.4m | — | |
| Unrealized change in fair value of biological assets | — | ($7.6m) | ($11.6m) | — | — | — | — | — | — | — | — | |
| Net changes in non-cash working capital | — | ($984k) | $4.7m | — | — | — | — | — | — | — | — | |
| Payment to exercise ABcann Global Corporation warrants | — | ($2.3m) | ($113k) | — | — | — | — | — | — | — | — | |
| Advances to joint ventures | — | $0 | ($6.9m) | — | — | — | — | — | — | — | — | |
| Cash flows used in investing activities | ($8.0m) | ($38.8m) | ($121.5m) | — | — | — | — | — | — | — | — | |
| Proceeds from exercise of warrants | $418k | $1.6m | $2.8m | — | — | — | — | — | — | — | — | |
| Proceeds from exercise of options | $104k | $591k | $584k | — | — | — | — | — | — | — | — | |
| Proceeds from share issuance | $18.0m | $49.6m | $146.0m | — | — | — | — | — | — | — | — | |
| Share issuance costs | ($162k) | ($2.8m) | ($9.6m) | — | — | — | — | — | — | — | — | |
| Proceeds from construction loan payable | — | $6.3m | $15.0m | — | — | — | — | — | — | — | — | |
| Repayment of mortgage payable | ($500k) | ($4.0m) | — | — | — | — | — | — | — | — | — | |
| Cash flows provided by financing activities | $16.8m | $50.1m | $154.6m | — | — | — | — | — | — | — | — | |
| Net change in cash | $2.3m | $5.7m | $23.4m | — | — | — | — | — | — | — | — | |
| Interest received | $48k | $22k | — | — | — | — | — | — | — | — | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.